47results about How to "Fast and effective early detection" patented technology

The invention discloses a molecular marker for clinical prognosis of pancreatic cancer. The molecular marker is one or more genes selected from LOC127841, LOC402377, GEMIN8P4 and SLC6A10P. The invention further discloses application of the molecular marker to preparation of a pancreatic cancer clinical prognosis reagent or a kit. The reagent or kit comprises one or more groups of primer sequences from specific amplification LOC127841, LOC402377, GEMIN8P4 and SLC6A10P. By using the one or more genes as the marker to detect pancreatic cancer, precision is improved greatly, early detection and prognosis evaluation can be achieved quickly and effectively, and the molecular marker is of great significance for diagnosis and treatment of pancreatic cancer.

The invention discloses an application of PCYOX1 (Prenylcysteine oxidase 1) protein as a biomarker of ischemic cerebral stroke, and particularly discloses the application of the PCYOX1 protein, an active fragment of the PCYOX1 protein or a substance for detecting the PCYOX1 protein or the active fragment of the PCYOX1 protein in a product for diagnosing ischemic cerebral stroke and/or evaluating the risk of suffering from ischemic cerebral stroke. The PCYOX1 protein related with cerebral stroke is provided, and down-regulated expression of the PCYOX1 protein or the active fragment of the PCYOX1 protein in the cerebral stroke tissue is further proved. With the adoption of the protein for detecting cerebral stroke, not only can early detection be realized rapidly and effectively, but also therapeutic targets and important basis are provided for clinical applications such as gene therapy, drug therapy and the like.

The invention discloses application of LOC80054 in diagnosis or prognosis of pancreatic cancer. The LOC80054 serves as a molecular marker. The invention further discloses the application of LOC80054 in preparing a diagnosis or prognosis kit for pancreatic cancer. The diagnosis or prognosis means diagnosis, therapeutic effect evaluation or metastatic recurrence monitoring. The molecular marker is utilized to screen, diagnose, treat, monitor and pre-diagnose the pancreatic cancer high risk group. LOC80054 has significance in diagnosing and treating pancreatic cancer.

The invention discloses an application of miR-1288 to preparation of a medicine for treating SHISA4 gene-related diseases, and a kit for diagnosing early osteoarthritis. The kit comprises a reagent for detecting the expression level of the miR-1288. The invention further discloses a medicine for treating the osteoarthritis. The medicine comprises a miR-1288 inhibitor. By the aid of miRNA for detecting the osteoarthritis, early detection can be rapidly and effectively realized, and therapeutic targets and important evidence are provided for clinical applications such as gene therapy and medicine therapy.

The invention discloses a molecular marker for detecting pancreatic cancer. The molecular marker is HCG4P6 and/or TOP1P2 gene. The invention further discloses application of the molecular marker in preparing a pancreatic cancer prognosis evaluation production. The invention further discloses a pancreatic cancer prognosis evaluation kit. The kit comprises a specific-amplification HCG4P and/or TOP1P2 primer sequence. By means of the molecular marker, diagnosis, treatment, monitoring and prognosis of the pancreatic cancer are processed, and the molecular marker has significance in prognosis and treatment of the pancreatic cancer.

The invention discloses a biomarker for detecting the ischemic cerebral stroke. The biomarker comprises KRT9 protein or active fragments thereof, mRNA coding the KRT9 protein, and a gene coding the KRT9 protein. The invention further discloses the KRT9 protein related to the cerebral stroke. Up-regulated expression of the KRT9 protein or the active fragments thereof in cerebral stroke tissue is further verified. By detecting the ischemic cerebral stroke with the protein, early detection can be rapidly and effectively achieved, and a therapeutic target and an important basis are provided for clinical application such as gene therapy and drug therapy.

The invention discloses a marker for detecting prostate. The marker is selected from one or more genes in PPIEL, RAET1K and/or MBL1P. The invention further discloses application of the marker in preparation of products of diagnosis and prognosis of prostate. The invention further discloses a kit for the diagnosis or the prognosis evaluation of the prostate. The kit comprises one or multiple groups of primer sequences in specifically amplified PPIEL, RAET1K and/or MBL1P. According to the marker, one or more genes are utilized as the marker for the combined detection of the marker, so that the early detection and the prognosis evaluation can be rapidly and efficiently realized, so that the accuracy is greatly improved, and furthermore, a therapeutic target and the important basis are provided for the clinical application including gene therapy, drug therapy and the like.

The invention discloses application of miR-146a as a marker in preparation of products for diagnosing steroid-induced femoral head necrosis. According to the application, expression of the miR-146a inbiological samples with steroid-induced femoral head necrosis is raised. According to the application, the products comprises a kit for diagnosing steroid-induced femoral head necrosis, and the kit comprises preparations for detecting the expression level of the miR-146a. By the adoption of the miR-146a to detect steroid-induced femoral head necrosis, not only can early detection be rapidly and effectively achieved, but also therapeutic targets and important evidence are provided for clinical application such as gene therapy and drug therapy.

The invention discloses a biomarker for detecting osteoarthritis. The biomarker comprises CRISP3 protein and/or CALML3 protein. The invention discloses the protein CRISP3 and/or CALML3 protein relatedto osteoarthritis, and down-regulated expression of the CRISP3 protein and/or CALML3 protein in urine is further confirmed. With the utilization of the protein for detecting osteoarthritis, rapid andeffective early detection can be achieved, and therapeutic targets and important basis are provided for clinical applications of gene therapy, drug therapy and the like.

The invention discloses application of an SPRR1A gene in preparation of an osteoarthritis diagnosis product, discloses the SPRR1A gene related to osteoarthritis and further proves down-regulation of the SPRR1A gene or expression proteins of the gene and fragments, analogs and derivatives of the gene in osteoarthritis tissue. By detecting osteoarthritis with the gene, it is possible to quickly and effectively provide early detection and also to provide a treatment target and an important basis for clinical application such as gene therapy and drug therapy.

The invention discloses a prostatic cancer diagnosis product and application thereof. The product can diagnose a prostatic cancer by detecting the expression level of LOC730668 in serum, urine and tissue specimens of a subject. The invention further discloses application of the product in prostatic cancer high risk group screening, diagnosing, treating, monitoring and prognosing. By utilizing the product to diagnose the prostatic cancer, not only can early detection be quickly and effectively achieved, but also a treatment target and an important basis are provided for clinical application such as gene therapy, drug therapy and the like.

The invention discloses an osteoarthritis diagnosing product; the product can diagnose osteoarthritis through detecting the expression level of a CRNN gene in a biological sample, or a CRNN gene expression protein and fragments, analogs and derivatives thereof. The invention further discloses an application of the product in diagnosis of osteoarthritis. The invention discloses the gene CRNN related with osteoarthritis, and down-regulated expression of the CRNN gene or the gene expression protein and fragments, analogs and derivatives thereof in osteoarthritis tissues is further confirmed. With use of the gene for detection of osteoarthritis, early detection can be rapidly and effectively done, and a therapeutic target and an important basis are provided for gene therapy, drug therapy and other clinical applications.

The invention discloses a marker for detecting prostatic cancer. The marker is selected from one or more genes of EFCAB10, MBL1P, PPIEL, RAET1K, RPL13AP6 and/or THSD1P1. The invention further discloses application of the marker to preparing prostatic cancer diagnosis and prognosis products. The invention further discloses a prostatic cancer diagnosis or prognosis evaluation kit. The kit comprises one or more groups of specifically amplified primer sequences in EFCAB10, MBL1P, PPIEL, RAET1K, RPL13AP6 and/or THSD1P1. According to the marker, one or more genes are used as markers for joint detection of the prostatic cancer, so that early detection and prognosis evaluation can be quickly and effectively realized, the precision is greatly increased, and additionally, a therapeutic target and an important basis are provided for clinical applications such as gene therapy and drug therapy.

The invention discloses an application of an MIF (migratory inhibitory factor) serving as a marker to preparation of a product for diagnosing steroid-induced avascular necrosis of the femoral head. Down-regulated expression of the MIF is achieved in biological samples with steroid-induced avascular necrosis of the femoral head. The application comprises a kit for diagnosing steroid-induced avascular necrosis of the femoral head, and the kit comprises a reagent for detecting the expression level of the MIF. The steroid-induced avascular necrosis of the femoral head is detected by an MIF gene, early detection can be rapidly and effectively achieved, and therapeutic targets and important bases are provided for clinical applications such as gene therapy and drug therapy.

The invention discloses an application of miR-495-5p in the preparation of products for diagnosis, prognosis, prevention or treatment of pancreatic cancer. The invention also provides a diagnostic kitfor detecting the pancreatic cancer. The invention further provides a medicinal composition for prognosis, prevention or treatment of the pancreatic cancer. The medicinal composition comprises an miR-495-5p inhibitor or a mimetic/analog thereof as an active ingredient. It is found that the miR-495-5p has a strong specificity and a high sensitivity, can be effectively used for early detection of the pancreatic cancer, and can be used for gene therapy, drug therapy and other clinical applications.

The invention discloses an application of long-chain acyl carnitine as a biomarker for cerebral arterial thrombosis, belongs to the field of biomedicine, and finds that the expression of the long-chain acyl carnitine in ischemic penumbra of a mouse acute cerebral arterial thrombosis model is up-regulated on the basis of a research technology of lipidomics and screening analysis of bioinformatics.Specifically, the invention relates to application of long-chain acyl carnitine in preparation of products for stroke diagnosis, risk assessment, diagnosis and treatment effect assessment of the severity degree of illness, prognosis recovery judgment and the like, early diagnosis, risk assessment and early warning of stroke can be rapidly and effectively carried out, and early diagnosis and earlywarning of stroke can also be rapidly and effectively carried out, and an important basis can be provided for evaluation and prognosis judgment of disease severity and treatment effect in the later period, and a treatment scheme of a doctor is assisted. In addition, the long-chain acyl carnitine disclosed by the invention can also provide a target for screening medicines for preventing and treating cerebral arterial thrombosis and clinical treatment.

The invention discloses a molecular marker detecting ischemic cerebralvascular accident. The molecular marker comprises PIGR protein or active fragments thereof, mRNA encoding the PIGR protein, and gene encoding the PIGR protein. The PIGR protein relevant to cerebralvascular accident is disclosed, and it is further proved that expression the PIGR protein or active fragments thereof is up-regulated in cerebralvascular tissue. By detecting ischemic cerebralvascular accident with the protein, early detection can be conducted quickly and effectively, and treating targets and important basis are provided for clinical application including gene therapy and drug therapy.

The invention discloses application of SNHG10 (small nucleolar RNA host gene 10) in the preparation of preparations for diagnosing prostate cancer. A preparation for diagnosing prostate cancer comprises detecting expression level of SNHG10 by using fluorescent quantitative PCR (polymerase chain reaction) method or a gene chip. The invention also discloses a kit for diagnosing prostate cancer, and the kit can detect the expression level of nucleotide sequence, as shown by SEQ ID NO: 1, in a biological sample in order to diagnose prostate cancer. The invention discloses SNHG10 associated with prostate cancer and further verifies that SNHG10 has expression downregulation in prostate cancer. By using SNHG10 to detect prostate cancer, it is possible to quickly and effectively achieve early detection, and treatment targets and important basis are provided for clinical applications such as gene therapy and drug therapy.

The invention discloses an application of MYCBP2-AS1 in preparation of products for diagnosis and treatment of cervical cancer, and further confirms that the expression of the MYCBP2-AS1 in a cervicalcancer tissue is up-regulated. The invention further discloses the MYCBP2-AS1 for preparing a diagnostic kit for detecting cervical cancer. The kit includes primers specifically amplifying cervical cancer-related lncRNA and instructions, wherein the cervical cancer-related lncRNA is the MYCBP2-AS1. The invention also discloses an MYCBP2-AS1 inhibitor, wherein the inhibitor includes siRNA of MYCBP2-AS1. The MYCBP2-AS1 is used for detecting cervical cancer, not only can early detection be quickly and effectively achieved, but also therapeutic targets and important basis are provided for clinical applications such as gene therapy and drug therapy.